Stockscreener 앱 받기
32.75
3.76%
-1.28
시간 외 거래:
32.75
전일 마감가:
$34.03
열려 있는:
$33.83
하루 거래량:
746.24K
Relative Volume:
1.58
시가총액:
$1.63B
수익:
$499.95M
순이익/손실:
$-36.36M
주가수익비율:
-42.53
EPS:
-0.77
순현금흐름:
$24.22M
1주 성능:
-10.15%
1개월 성능:
-5.92%
6개월 성능:
+9.09%
1년 성능:
-2.70%
1일 변동 폭
$32.72
$34.59
1주일 범위
$30.93
$37.28
52주 변동 폭
$28.29
$43.11
Atricure Inc Stock (ATRC) Company Profile
명칭
Atricure Inc
전화
513-755-4100
주소
7555 INNOVATION WAY, MASON, OH
ATRC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
32.75 | 1.69B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
538.82 | 192.92B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
179.04 | 50.82B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
74.19 | 36.53B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
RMD
Resmed Inc
|
246.40 | 36.34B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
286.94 | 20.13B | 2.96B | 487.70M | 344.00M | 6.6758 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 재개 | JP Morgan | Overweight |
| 2024-04-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-29 | 개시 | UBS | Buy |
| 2021-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 재확인 | Needham | Buy |
| 2020-11-06 | 재확인 | Needham | Buy |
| 2020-04-07 | 개시 | Oppenheimer | Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2020-01-24 | 재확인 | Needham | Buy |
| 2019-08-13 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 개시 | JP Morgan | Overweight |
| 2018-10-04 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Stifel | Buy |
| 2018-06-18 | 재확인 | Needham | Buy |
| 2018-04-27 | 재확인 | Needham | Buy |
| 2018-01-16 | 재확인 | Needham | Buy |
| 2017-11-02 | 재확인 | Needham | Buy |
| 2017-07-28 | 재확인 | Needham | Buy |
| 2017-05-30 | 재개 | Piper Jaffray | Overweight |
| 2016-06-30 | 재개 | JMP Securities | Mkt Outperform |
| 2015-10-28 | 재확인 | Needham | Buy |
| 2015-10-06 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-06 | 재확인 | Needham | Buy |
모두보기
Atricure Inc 주식(ATRC)의 최신 뉴스
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Cardiac Ablation Market to Reach USD 18.7 Billion by 2034 - openPR.com
AtriCure Inc. stock trendline breakdownJuly 2025 Update & Safe Capital Allocation Plans - newser.com
How rising interest rates impact AtriCure Inc. stock2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
Why AtriCure Inc. stock attracts high net worth investorsJuly 2025 Action & Target Return Focused Picks - newser.com
What’s the recovery path for long term holders of AtriCure Inc.Profit Target & Free High Return Stock Watch Alerts - newser.com
Can AtriCure Inc. stock beat market expectations this quarter2025 Macro Impact & Verified Momentum Watchlists - newser.com
AtriCure Insiders Sold US$607k Of Shares Suggesting Hesitancy - 富途牛牛
Why AtriCure Inc. stock remains undervaluedWeekly Trend Report & AI Powered Market Entry Ideas - newser.com
Is AtriCure Inc. stock near bottom after declinePortfolio Update Summary & Risk Managed Trade Strategies - newser.com
How sustainable is AtriCure Inc. stock dividend payoutJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
AtriCure, Inc. $ATRC Stake Raised by Nicholas Company Inc. - MarketBeat
Is AtriCure Inc. stock overvalued by current metricsWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
Why AtriCure Inc. stock is recommended by analysts2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
AtriCure (ATRC) Is Down 8.0% After Raising 2025 Guidance and Reporting Narrower LossesHas The Bull Case Changed? - simplywall.st
Analyzing drawdowns of AtriCure Inc. with statistical tools2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Does AtriCure Inc. qualify in momentum factor screeningTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Exit strategy if you’re trapped in AtriCure Inc.Bull Run & Stepwise Swing Trade Plans - newser.com
Intraday pattern recognizer results for AtriCure Inc.Weekly Profit Analysis & Stock Portfolio Risk Management - newser.com
AtriCure, Inc. (ATRC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth - MSN
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation - MSN
AtriCure’s Earnings Call Highlights Robust Growth and Innovation - The Globe and Mail
AtriCure, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ATRC) 2025-10-31 - Seeking Alpha
AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia - MSN
AtriCure (NASDAQ:ATRC) Sees Large Volume Increase on Strong Earnings - MarketBeat
AtriCure (ATRC) Losses Worsen 12.8% Annually, Challenging Bullish Profitability Narratives - Sahm
Atricure (ATRC) Gets a Buy from Canaccord Genuity - The Globe and Mail
AtriCure (ATRC) Margin Miss Challenges Hopes for Near-Term Profitability Despite Strong Growth Forecasts - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
AtriCure Inc. stock trend forecastInsider Selling & Smart Allocation Stock Tips - newser.com
Why AtriCure Inc. stock is seen as undervaluedRate Cut & AI Optimized Trading Strategy Guides - newser.com
Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results - Investing.com Nigeria
AtriCure stock maintains Buy rating at Needham following strong Q3 results - Investing.com Nigeria
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - MedTech Intelligence
AtriCure stock maintains Buy rating at Needham following strong Q3 results By Investing.com - Investing.com South Africa
Atricure Inc (ATRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.48%
0.69%
자본화:
|
볼륨(24시간):